Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from HUTCHMED (China) ( (HK:0013) ).
HUTCHMED (China) Limited has published its Form 20-F for the financial year ended December 31, 2025, making the annual filing available to investors and stakeholders via its website and regulatory disclosure platforms. The release underlines the company’s ongoing transparency as a global biopharmaceutical player listed in Hong Kong, on Nasdaq and AIM, and provides the market with updated financial and operational information that will inform investor assessment of its progress and strategy.
More about HUTCHMED (China)
HUTCHMED (China) Limited is an innovative, commercial-stage biopharmaceutical company focused on discovering, developing and commercializing targeted therapies and immunotherapies for cancer and immunological diseases. It has brought multiple in-house discovered drug candidates to market, with three medicines already marketed in China and one approved internationally, including in the US, Europe and Japan.
Find detailed analytics on 0013 stock on TipRanks’ Stock Analysis page.